Drugs / IDflu
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | IDflu | — | 2018-03-19 | europa.eu ↗ |
| Approved | EU (EMA) | IDflu | — | 2009-02-24 | europa.eu ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01215669 | Oct 2010 → Feb 2011 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02398097 Comparator | Nov → Dec 2011 | influenza | Korea University Guro Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDflu | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01215669 ↗ |
| Known as | Intanza() | “Intanza(®)/IDflu(®) (Sanofi Pasteur, Lyon, France) is an intradermal inactivated trivalent influenza vaccine developed as an alternative to intramuscular influenza vaccine.” PMID 23778938 ↗ Jun 2013 |
| Modality | Vaccine | “intradermal inactivated trivalent influenza vaccine” PMID 23778938 ↗ Jun 2013 |
| Route | Intravenous | “Single dose 0.1 mL, intradermal” NCT01215669 ↗ |